Ferroptosis and Alzheimer’s disease: Neuroimmune crosstalk and pharmacological opportunities
Brain Research · 2026
DOI: 10.1016/j.brainres.2026.150514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Research, 2026. Verfasst von Yelizaveta A Marakhovskaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University (Pirogov University), Moscow 129226, Russia. E…. Hauptthemen laut MEDLINE: Ferroptosis, Alzheimer Disease, Neuroimmunomodulation. Die Arbeit nennt 118 Literaturangaben. Gefördert von: Ministry of Health of the Russian Federation.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) develops through interacting proteinopathic, metabolic, oxidative, and neuroimmune processes. Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation and failure of antioxidant defense systems. This review examines the bidirectional interface between ferroptosis and neuroinflammation in AD and distinguishes direct AD-related evidence from findings derived from experimental models and broader ferroptosis or inflammatory studies. Iron dyshomeostasis, impaired ferroportin-dependent iron export, lipid peroxidation, and reduced glutathione/GPX4-dependent protection may increase neuronal susceptibility to ferroptotic injury. In turn, oxidized lipids and danger-associated molecular patterns released from damaged neurons may activate microglia and astrocytes, engage inflammasome and complement signaling, and amplify inflammatory responses. Conversely, cytokine signaling, altered iron handling, and immune-cell redox and lipid remodeling may further increase ferroptotic vulnerability. We also compare ferroptosis-related markers and pathways in neurons, microglia, and astrocytes and discuss potential therapeutic approaches targeting iron metabolism, lipid peroxidation, GPX4 activity, system xc - function, NRF2-related antioxidant defense, neuroimmune signaling, and multitarget compounds. Although available evidence supports an association between ferroptosis-related processes and AD pathobiology, no single marker is sufficient to establish ferroptosis in human AD tissue. This limitation currently restricts the diagnostic and therapeutic interpretation of ferroptosis in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University (Pirogov University), Moscow 129226, Russia. Electronic address: marahovskaya_ea@rgnkc.ru.
- Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University (Pirogov University), Moscow 129226, Russia. Electronic address: achurou@yandex.ru.
- Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University (Pirogov University), Moscow 129226, Russia. Electronic address: arbatsky_ms@rgnkc.ru.
- Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow 119048, Russia.…
Förderung
- Ministry of Health of the Russian Federation
Zitieren
APA
Marakhovskaya, Y. A., Churov, A. V., Arbatsky, M. S., & Sergeeva, S. P. (2026). Ferroptosis and Alzheimer’s disease: Neuroimmune crosstalk and pharmacological opportunities. Brain Research. https://doi.org/10.1016/j.brainres.2026.150514
Vancouver
Marakhovskaya YA, Churov AV, Arbatsky MS, Sergeeva SP. Ferroptosis and Alzheimer’s disease: Neuroimmune crosstalk and pharmacological opportunities. Brain Research. 2026. doi:10.1016/j.brainres.2026.150514
BibTeX
@article{Marakhovskaya2026,
author = {Marakhovskaya, Yelizaveta A and Churov, Alexey V and Arbatsky, Mikhail S and Sergeeva, Svetlana P},
title = {Ferroptosis and Alzheimer’s disease: Neuroimmune crosstalk and pharmacological opportunities},
journal = {Brain Research},
year = {2026},
doi = {10.1016/j.brainres.2026.150514}
}
EUVIMED